The BRAF Tests market presents significant opportunities in melanoma treatment, driven by technological advancements and regulatory insights. Key opportunities lie in market segmentation, emerging ...
This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the transfer time, which can be streamlined by pathology reflex testing. Delays in TAT affect the timing ...
Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions. The Food and Drug Administration (FDA) has granted accelerated approval to ...
Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of ...
A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, "Targeting the multifaceted BRAF in cancer: New directions." In cancer patients, BRAF-targeting precision ...
Dec 15 (Reuters) - Biocartis Group Nv : * Biocartis Group: CE-marking Idylla NRAS-BRAF mutation test completes offering of metastatic colorectal cancer tests for clinical use on Idylla platform Source ...
Biomarker testing completion rates in patients with metastatic colorectal cancer (CRC) has increased over time in alignment with guidelines and US Food and Drug Administration (FDA) approvals, but ...
In patients with skin or lung cancer, drugs that inhibit BRAF (v-raf murine sarcoma viral oncogene homolog B) mutations increase the risk for uveitis dramatically compared with conventional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback